Abstract
Background Respiratory syncytial virus (RSV) and influenza virus are major viral etiologies of pediatric lower respiratory tract infection, but comparative data on inpatient burden are lacking.
Methods Using a large-scale health claims database in Japan, we identified patients under 5 years of age with a confirmed RSV or influenza diagnosis as an outpatient or inpatient between 2011-2022. Hospitalization rate, inpatient characteristics, various in-hospital outcomes/complications, and healthcare resource utilization were described.
Results A total of 176,911 RSV-confirmed outpatients, 153,383 influenza-confirmed outpatients, 90,413 RSV-confirmed hospitalizations, and 11,186 influenza-confirmed hospitalizations were identified. Among outpatients, 24.7% of RSV infection and 2.8% of influenza cases required hospitalization within one week. There was no comorbidities/prematurity for 95.0% of RSV hospitalizations and 96.5% of influenza hospitalizations. Proportions of in-hospital outcomes/complications were (RSV infection vs influenza): oxygen use 47.6% vs 14.8%, mechanical ventilation 2.1% vs 0.7%, pneumonia 33.6% vs 12.8%, otitis media 7.7% vs 2.3%, febrile seizure 1.5% vs 34.4%, encephalitis/encephalopathy 0.1% vs 0.5%, myocarditis <0.1% vs 0.6%, antibiotics prescription 48.0% vs 24.4%. The mean inpatient stay was 6.1 vs 4.3 days at direct medical costs of 435,744 vs 315,809 JPY/patient. These trends held true in age-stratified data. In-hospital death occurred in 31 RSV infection and 6 influenza cases.
Conclusions Although both infections resulted in substantial burden, RSV infection led to more frequent hospitalizations, worse in-hospital outcomes, longer inpatient stays, higher medical costs, and more frequent antibiotics prescription compared to influenza. Most RSV hospitalizations occurred among healthy term children, emphasizing the need for prevention measures in all children.
Competing Interest Statement
Takeshi Arashiro is a Sanofi employee and a cooperative researcher at the National Institute of Infectious Diseases, Japan. Rolf Kramer, Jing Jin, and Munehide Kano are Sanofi employees. Fangyuan Wang is a Syneos Health employee. Isao Miyairi received honoraria from Sanofi for lectures and advisory committees.
Funding Statement
This work was supported by Sanofi and AstraZeneca.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was obtained from the ethic review board of Tokyo Allergy and Respiratory Disease Research Institute.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
